Literature DB >> 18383118

Regression of symptoms after selective iron chelation therapy in a case of neurodegeneration with brain iron accumulation.

Gian Luca Forni1, Manuela Balocco, Laura Cremonesi, Giovanni Abbruzzese, Roberto Carlo Parodi, Roberta Marchese.   

Abstract

We report the results of iron chelating treatment with deferiprone in a 61-year-old woman with signs and symptoms of neurodegeneration with brain iron accumulation (NBIA). After 6 months of therapy the patient's gait had improved and a reduction in the incidence of choreic dyskinesias was observed. Her gait returned to normal after an additional 2 months of therapy, at which time there was a further reduction in involuntary movements and a partial resolution of the blepharospasm. (c) 2008 Movement Disorder Society.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18383118     DOI: 10.1002/mds.22002

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  23 in total

1.  As iron goes, so goes disease?

Authors:  Susan J Hayflick; Penelope Hogarth
Journal:  Haematologica       Date:  2011-11       Impact factor: 9.941

2.  A role for sex and a common HFE gene variant in brain iron uptake.

Authors:  Kari A Duck; Elizabeth B Neely; Ian A Simpson; James R Connor
Journal:  J Cereb Blood Flow Metab       Date:  2017-03-28       Impact factor: 6.200

3.  A pilot trial of deferiprone for neurodegeneration with brain iron accumulation.

Authors:  Giovanni Abbruzzese; Giovanni Cossu; Manuela Balocco; Roberta Marchese; Daniela Murgia; Maurizio Melis; Renzo Galanello; Susanna Barella; Gildo Matta; Uberto Ruffinengo; Ubaldo Bonuccelli; Gian Luca Forni
Journal:  Haematologica       Date:  2011-07-26       Impact factor: 9.941

4.  Involvement of globus pallidus and midbrain nuclei in pantothenate kinase-associated neurodegeneration: measurement of T2 and T2* time.

Authors:  R Fermin-Delgado; P Roa-Sanchez; H Speckter; E Perez-Then; D Rivera-Mejia; B Foerster; P Stoeter
Journal:  Clin Neuroradiol       Date:  2012-01-19       Impact factor: 3.649

5.  Multifunctional antioxidants for the treatment of age-related diseases.

Authors:  Hongxia Jin; James Randazzo; Peng Zhang; Peter F Kador
Journal:  J Med Chem       Date:  2010-02-11       Impact factor: 7.446

6.  Treatment of classic pantothenate kinase-associated neurodegeneration with deferiprone and intrathecal baclofen.

Authors:  Napala R Pratini; Nancy Sweeters; Elliott Vichinsky; Jacob A Neufeld
Journal:  Am J Phys Med Rehabil       Date:  2013-08       Impact factor: 2.159

7.  Selective inhibition of hypoxia-inducible factor (HIF) prolyl-hydroxylase 1 mediates neuroprotection against normoxic oxidative death via HIF- and CREB-independent pathways.

Authors:  Ambreena Siddiq; Leila R Aminova; Carol M Troy; Kyungsun Suh; Zachary Messer; Gregg L Semenza; Rajiv R Ratan
Journal:  J Neurosci       Date:  2009-07-08       Impact factor: 6.167

Review 8.  Neuroimaging features of neurodegeneration with brain iron accumulation.

Authors:  M C Kruer; N Boddaert; S A Schneider; H Houlden; K P Bhatia; A Gregory; J C Anderson; W D Rooney; P Hogarth; S J Hayflick
Journal:  AJNR Am J Neuroradiol       Date:  2011-09-15       Impact factor: 3.825

9.  Gossypitrin, A Naturally Occurring Flavonoid, Attenuates Iron-Induced Neuronal and Mitochondrial Damage.

Authors:  María Ángeles Bécquer-Viart; Adonis Armentero-López; Daniel Alvarez-Almiñaque; Roberto Fernández-Acosta; Yasser Matos-Peralta; Richard F D'Vries; Javier Marín-Prida; Gilberto L Pardo-Andreu
Journal:  Molecules       Date:  2021-06-02       Impact factor: 4.411

Review 10.  New Era in the Treatment of Iron Deficiency Anaemia Using Trimaltol Iron and Other Lipophilic Iron Chelator Complexes: Historical Perspectives of Discovery and Future Applications.

Authors:  George J Kontoghiorghes; Annita Kolnagou; Theodora Demetriou; Marina Neocleous; Christina N Kontoghiorghe
Journal:  Int J Mol Sci       Date:  2021-05-24       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.